Literature DB >> 9849072

Clinical pharmacology and therapeutic drug monitoring in neonates and children.

R Loebstein1, G Koren.   

Abstract

From a pharmacotherapy perspective, the process of development and growth represents an unstable and dynamic condition. Age-related changes in drug absorption, distribution, and metabolism among neonates, infants, and prepubescent children create a unique situation that may increase drug toxicity of some agents and protect from toxicity of other agents. Understanding the age-related changes in drug disposition that are relevant for therapeutic response and toxicity is essential for optimizing pharmacotherapy at different stages of childhood.

Entities:  

Mesh:

Year:  1998        PMID: 9849072     DOI: 10.1542/pir.19-12-423

Source DB:  PubMed          Journal:  Pediatr Rev        ISSN: 0191-9601


  12 in total

Review 1.  Review: therapeutic drug monitoring in pediatrics.

Authors:  Offie Porat Soldin; Steven J Soldin
Journal:  Ther Drug Monit       Date:  2002-02       Impact factor: 3.681

2.  A step forward towards accurately assessing glomerular filtration rate in newborns.

Authors:  Guido Filler
Journal:  Pediatr Nephrol       Date:  2015-05-05       Impact factor: 3.714

3.  Prediction of drug clearance in children: an evaluation of the predictive performance of several models.

Authors:  Iftekhar Mahmood; Carl-Michael Staschen; Kosalaram Goteti
Journal:  AAPS J       Date:  2014-10-02       Impact factor: 4.009

Review 4.  Identifying genomic and developmental causes of adverse drug reactions in children.

Authors:  Mara L Becker; J Steven Leeder
Journal:  Pharmacogenomics       Date:  2010-11       Impact factor: 2.533

5.  Population pharmacokinetics and dosing regimen design of milrinone in preterm infants.

Authors:  Mary Paradisis; Xuemin Jiang; Andrew J McLachlan; Nick Evans; Martin Kluckow; David Osborn
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2006-05-11       Impact factor: 5.747

6.  Autoantibodies against cytochrome P450s in sera of children treated with immunosuppressive drugs.

Authors:  S D Lytton; U Berg; A Nemeth; M Ingelman-Sundberg
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

Review 7.  Dosing in neonates: special considerations in physiology and trial design.

Authors:  Lawrence C Ku; P Brian Smith
Journal:  Pediatr Res       Date:  2014-09-30       Impact factor: 3.953

Review 8.  Dosing in children: a critical review of the pharmacokinetic allometric scaling and modelling approaches in paediatric drug development and clinical settings.

Authors:  Iftekhar Mahmood
Journal:  Clin Pharmacokinet       Date:  2014-04       Impact factor: 6.447

9.  Carboplatin therapeutic monitoring in preterm and full-term neonates.

Authors:  Gareth J Veal; Julie Errington; James Hayden; David Hobin; Dermot Murphy; Rachel M Dommett; Deborah A Tweddle; Helen Jenkinson; Susan Picton
Journal:  Eur J Cancer       Date:  2015-07-29       Impact factor: 9.162

10.  Allometric Scaling of Clearance in Paediatric Patients: When Does the Magic of 0.75 Fade?

Authors:  Elisa A M Calvier; Elke H J Krekels; Pyry A J Välitalo; Amin Rostami-Hodjegan; Dick Tibboel; Meindert Danhof; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2017-03       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.